-
公开(公告)号：EP1580193A3
公开(公告)日：2010-06-23
申请号：EP04030774.6
申请日：2000-12-04
发明人： Barton, Kathleen P. , Gaud, Henry T. , Ganser, Scott , Little, Clay R. , Mudipalli, Partha S. , Borschardt, Thomas B. , Carlos, Marlon V. , Desai, Subhash , Ferro, Leonard J. , Pietz, Mark A. , Sing, Yuen-Lung L. , Stahl, Glenn L. , Wieczorek, Joseph J. , Yan, Chris Y.
CPC分类号： C07J71/0015
摘要： A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.
-
公开(公告)号：EP2172199A1
公开(公告)日：2010-04-07
申请号：EP09178277.1
申请日：2003-07-25
发明人： Amidon, Gregory, E. , Ganorkar, Loksidh, D. , Heimlich, John, M. , Lee, Ernest, J. , Martino, Alice, C. , Noack, Robert, M. , Reo, Joseph, P. , Skoug, Connie, J.
IPC分类号： A61K31/428 , A61K9/20 , A61K9/28
CPC分类号： A61K31/428 , A61K9/2054 , A61K9/2059 , A61K9/2866 , A61K31/4745 , A61K31/5375
摘要： A sustained - release pharmaceutical composition in a form of an orally deliverable tablet comprising an active pharmaceutical agent having solubility not less than about 10mg/ml, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15kNcm -2 at a solid fraction representative of the tablet.
摘要翻译： 一种口服递送片剂形式的缓释药物组合物，其包含分散在含有亲水聚合物和抗张强度至少约0.15kNcm的淀粉的基质中的溶解度不小于约10mg / ml的活性药剂 -2代表片剂的固体部分。
-
3.发明公开N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof. 审中-公开N-末端单PEG人体生长激素的缀合物，其制造方法和使用的方法
公开(公告)号：EP1915999A1
公开(公告)日：2008-04-30
申请号：EP07110559.7
申请日：2005-01-24
发明人： Finn, Rory, F.
IPC分类号： A61K38/27
摘要： The present invention provides a chemically modified human Growth Hormone (hGH) prepared by attaching a polyethylene glycol butyraldehyde moiety to the N-terminal phenylalanine of the protein. The chemically modified protein according to the present invention may have a much longer lasting hGH activity than that of the un-modified hGH, enabling reduced dose and scheduling opportunities. The present invention also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
摘要翻译： 本发明提供了通过聚乙二醇丁醛部分连接到蛋白质的N-末端苯丙氨酸制备的化学修饰的人生长激素（hGH）。 化学修饰的蛋白质gemäß到本发明可具有比未修饰的hGH的更长持久的hGH的活性，使得能够减少剂量和调度机会。 因此，本发明包括用于疾病或病症的治疗和/或预防其中使用生长激素是有利的使用方法。
-
4.发明授权USE OF AN ALDOSTERONE ANTAGONIST FOR THE TREATMENT OR PROPHYLAXIS OF ALDOSTERONE-MEDIATED PATHOGENIC EFFECTS 有权一醛固酮拮抗剂醛固酮介导的病原性病症的治疗和预防
公开(公告)号：EP1289507B1
公开(公告)日：2008-02-13
申请号：EP00978588.2
申请日：2000-11-14
发明人： WILLIAMS, Gordon, H. , FUNDER, John, W. , GARTHWAITE, Susan, M. , RONIKER, Barbara , FEDDE, Kenton, N. , ROCHA, Ricardo
IPC分类号： A61K31/00 , A61K31/585 , A61P43/00 , A61P9/00 , A61P9/12 , A61P9/04 , A61P7/10 , A61P9/10 , A61P13/12
CPC分类号： A61K31/56 , A61K31/00 , A61K31/415 , A61K31/4152 , A61K31/437 , A61K31/5513 , A61K31/57 , A61K31/58 , A61K31/585 , A61K45/06 , A61K2300/00
摘要： The present invention provides methods for the treatment or porphylaxis of one or more aldosterone-mediated pathogenic effects in a subject suffering from or susceptible to the pathogenic effect or effects wherein the subject has one or more conditions selected from the group consisting of a sub-normal endogenous aldosterone level, salt sensitivity and an elevated dietary sodium intake. The methods comprise administering to the subject a therapeutically-effective amount of one or more epoxy-steroidal compounds that are aldosterone antagonists.
-
5.发明授权COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND AN HMG COA REDUCTASE INHIBITOR 有权组合的醛固酮受体拮抗剂和一个HMG CoA还原酶抑制剂
公开(公告)号：EP1406660B1
公开(公告)日：2007-06-06
申请号：EP02756521.7
申请日：2002-07-18
IPC分类号： A61K45/06 , A61K31/585 , A61K31/44 , A61K31/40 , A61K31/365 , A61K31/22 , A61P9/00
CPC分类号： A61K45/06 , A61K31/22 , A61K31/365 , A61K31/40 , A61K31/44 , A61K31/4747 , A61K31/585 , A61K2300/00
摘要： Novel methods and combinations for the treatment and/or prophylaxis of a pathologic condition in a subject, wherein the methods comprise the administration of one or more HMG Co-A reductase inhibitors and one or more aldosterone receptor antagonists, and the combinations comprise one or more HMG Co-A reductase inhibitors and one or more of said aldosterone receptor antagonists.
-
6.发明公开COMPOSITIONS FOR TREATMENT OF INFLAMMATION AND PAIN USING A COMBINATION OF A COX-2 SELECTIVE INHIBITOR AND A LTB4 RECEPTOR ANTAGONIST 审中-公开组合物用于治疗炎症和疼痛与COX-2选择性抑制剂的组合，并且甲LTB4受体拮抗剂
公开(公告)号：EP1773396A1
公开(公告)日：2007-04-18
申请号：EP05759420.2
申请日：2005-07-11
IPC分类号： A61K45/06 , A61K31/353 , A61P29/00
CPC分类号： A61K45/06 , A61K31/353 , A61K2300/00
摘要： The present invention provides a therapeutic composition comprising a COX-2 selective inhibitor or a prodrug thereof and an LTB4 receptor antagonist. A method is provided for the use of such composition in the treatment, prevention, or inhibition of inflammation, an inflammation-related disorder, pain, or a pain-related disorder.
-
7.发明授权EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE 有权与用于治疗充血性心脏衰竭环氧甾体醛固酮拮抗剂和钙通道阻滞剂合用治疗
公开(公告)号：EP1303305B1
公开(公告)日：2007-03-21
申请号：EP01956001.0
申请日：2001-07-27
IPC分类号： A61K45/06 , A61K31/58 , A61P9/00 , A61K31/275
CPC分类号： A61K31/58 , A61K31/585 , A61K45/06 , A61K31/275 , A61K2300/00
摘要： A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a calcium channel blocker is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred calcium channel blockers are those compounds having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 2O-spiroxane steroidal compounds characterized by the presence of a 9alpha,11alpha-substituted epoxy moiety. A preferred combination therapy includes the calcium channel blocker verapamil HC1 (Benzenacetonitrile, (±) -alpha[3[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)hydrochloride) and the aldosterone receptor antagonist epoxymexrenone.
-
8.发明公开METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PSYCHIATRIC DISORDERS WITH COX-2 INHIBITORS ALONE AND IN COMBINATION WITH ANTIDEPRESSANT AGENTS 审中-公开方法和组合物治疗或精神疾病的预防与COX-2抑制剂单独或与抗抑郁药组合
公开(公告)号：EP1725222A2
公开(公告)日：2006-11-29
申请号：EP05724377.6
申请日：2005-03-02
IPC分类号： A61K31/00 , A61K31/635 , A61K31/415 , A61K45/06 , A61P25/00 , A61P25/18 , A61P25/22 , A61P25/24
CPC分类号： A61K31/00 , A61K31/415 , A61K31/635
摘要： The present invention relates to a novel method of treating and/or preventing psychiatric disorders in a subject by administering to the subject at last one Cox-2 inhibitor alone or in combination with one or more antidepressant agents. Compositions, pharmaceutical compositions and kits are also described.
-
公开(公告)号：EP1545994B1
公开(公告)日：2006-11-15
申请号：EP03793140.9
申请日：2003-08-20
发明人： MACLEOD, Steven, K.
CPC分类号： A61J1/2093 , A61J1/1406 , A61J1/201 , A61J1/2041 , A61J1/2096 , A61K9/0019 , A61K47/02 , A61K47/10 , A61K47/183 , A61K47/26 , A61K47/32 , B65D25/082
摘要： An article of manufacture is provided comprising a vial having (a) a first chamber that is substantially filled with an injectable pharmaceutical formulation; (b) a second chamber that is substantially empty but for a gaseous medium; (c) a septum, impermeable to the gaseous medium, separating the first and second chambers; and (d) actuating means effective to bring the formulation and the gaseous medium into contact by breach of the septum such that the gaseous medium acts as an effective headspace for agitation of the formulation. The formulation comprises an aqueous medium, a drug in solid particulate form in a therapeutically effective amount suspended in the medium, and one or more wetting and/or suspending agents in an amount effective to provide controlled flocculation of the drug, at least one ingredient of the formulation being susceptible to oxidative degradation.
-
公开(公告)号：EP1471890B1
公开(公告)日：2006-09-27
申请号：EP03710927.9
申请日：2003-02-06
IPC分类号： A61K9/34
CPC分类号： A61K9/286 , A61K9/0056 , A61K9/006
摘要： A pharmaceutical tablet is provided comprising an intraorally disintegratable core and an excipient coating adherent thereto, wherein the coating comprises gellan gum. The tablet is suitable for intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject, at least in part by absorption of the drug via oral mucosa of the subject.
-
-
-
-
-
-
-
-
-
搜索结果
363 条记录 (耗时 0.037 秒)
